

Electronic Platform for Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy (LAUGH TRACK UMN)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Up to 18 years old

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- girls ages 2-11 years - boys ages 2-13 years - established diagnosis of pediatric growth hormone deficiency (GHD). - For this study, GHD is defined as peak growth hormone response to clonidine/arginine stimulation testing of <10 ng/mL Either treatment-naive or currently treated with a daily growth hormone as approved by health insurance.

Exclusion Criteria:

- any medical condition which, in the opinion of the Investigator, can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment - current treatment with long-acting growth hormone - currently pregnant or breastfeeding

Conditions & Interventions

Interventions:

Drug: Long-Acting Growth Hormone (LAGH)

Conditions:

Children's Health, Diabetes & Endocrine

Keywords:

Growth Hormone Deficiency

More Information

Description: The purpose of the study is to compare quality of life (QOL), adherence, insulin resistance, body composition and efficacy of LAGH to DGH in children with GHD.

Study Contact: Brad Miller - mille685@umn.edu

Principal Investigator: Brad Miller, MD, PhD

IRB

Number: STUDY00011784

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.